Stock IGXT INTELGENX TECHNOLOGIES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Market Closed - OTC Markets
Other stock markets
 03:57:54 2024-05-16 pm EDT 		5-day change 1st Jan Change
0.167 USD -3.75% Intraday chart for IntelGenx Technologies Corp. +1.83% +20.93%
May. 21 IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives MT
May. 17 IntelGenx Brief: Initiating Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IntelGenx Technologies Corp. Announces Board Resignations
IntelGenx Technologies Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm
IntelGenx Technologies Corp. Announces Changes to its Board of Directors
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Intelgenx Technologies Corp. Announces Co-Development and Commercialization of Cannabinoid-Infused Versafilm® Products with Tilray
Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States
Intelgenx Corp. Receives the First Purchase Order for Rizafilm
IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
IntelGenx Closes First Tranche of Private Placement From Strategic Partner For Aggregate Proceeds of US$3 Million
Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
IntelGenx Technologies Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IGXT Stock
  4. News IntelGenx Technologies Corp.
  5. Other languages
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW